chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was administered 0.5ml instead of 0.25ml of booster 3rd dosage, patient was called and denies any problems since vaccination. Letter was sent informing patient of dosage given
had a sore arm; her head felt heavy; This is a spontaneous report from a contactable consumer (parent). A contactable consumer (parent) reported for a female of unknown age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number/Exp. date unknown) on 23Dec2020 at single dose for covid-19 immunisation. Medical history and concomitant medication were not provided. The patient stated that she received her first dose of the Covid-19 vaccine on 23Dec and had a sore arm and her head felt heavy. She was normal by the next day. The events outcome was recovered on 24Dec2020.    The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
On 9/22/00, pt presents with right arm "rubbing, tender, slightly swollen and with maculo-papular irregular erythema.
Night of injection: Chills for several hours, extreme joint paint, muscle pain, headache, took 2 500mg Tylenol  Next day, 4/1/21: moderate headache, moderate muscle soreness, fatigue, weakness, took 4 500mg Tylenol throughout day  4/2/21: afternoon fatigue and weakness, headache in afternoon that worsened throughout the night, took 2 500mg Tylenol  4/3/21: severe headache, weakness, loss of appetite and nausea (could be due to acid reflux flaring up), took 4 excedrin migraine throughout the day and 1 Nexium 24hr at night
Minor redness/swelling on vaccine day on bilateral arms. Increasing redness and swelling starting the following morning on both arms. Ibuprofen and Benadryl as needed. Mother to call if redness passes border markings.
1/5, child in w/father c/o "itching rash" & reddened macular papular rash on upper extremities bilateral & upper part of back, few blistered areas noted. Pt is afebrile, referred to PCP if worse. 1/10, rash remains & is now on hands.
Patient called nurse triage stating had 4 inch red, warm circle on arm where received her shingles vaccine. Patient was offered an appointment but declined and stated will continue with home care. Applying hydrocortisone cream to area and oral BENADRYL as needed. Advised appointment if any difficulty breathing or red streak appears.
Patients mother called clinic and notified us that patient woke this morning, 7/20/2022, with swelling  of the face, mother stated that she was acting fine and had no signs of dyspnea
Delayed hives approximately 48 hours after shot. No other known causes for reaction. Took benadryl and zyrtec to cope with hives and reduce itching.
Patient was fully vaccinated and boosted, developed COVID19 on 01/05/2022, and passed away on 01/12/2022. mortality review team is currently investigating this death to determine if it was COVID19 related.
Patient up to date on COVID vaccinations, last dose 12/16/21 who admitted with COVID complications.  Provider discharge note below:  "72 YO F with history of COPD with chronic respiratory failure on 2LNC, lung cancer, HFpEF, ongoing tobacco abuse who was admitted with acute on chronic respiratory failure due to COVID-19 pneumonia, acute exacerbation of COPD. She was treated with steroids, remdesivir, and nebulizer therapy for COVID-19 pneumonia and COPD exacerbation. She also received a course of antibiotics for community acquired pneumonia. She had initially progression of symptom and required 100% oxygen by non-rebreather for multiple days. She then had slow improvement and was weaned back down to 5L NC. She was feeling well and able to ambulate on 5L without hypoxia. Monitored for over 24h on 5L without further hypoxia. Discharged home in good condition.    Will continue prednisone taper on discharge. Otherwise no change in medications. "
Covid test date=Oct2022 / Covid test result=Positive; Covid test date=Oct2022 / Covid test result=Positive; This is a spontaneous report received from a contactable reporter(s) (Physician).  A 61-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 01Jan2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 29Jan2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 20Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 60 years, in left arm, all intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Sulfa" (unspecified if ongoing), notes: Known allergies: Sulfa; "Known allergies: Penicillin" (unspecified if ongoing), notes: Known allergies: Penicillin; "glaucoma" (unspecified if ongoing); "If covid Prior vaccination: Yes" (unspecified if ongoing), notes: If covid Prior vaccination: Yes. There were no concomitant medications. Past drug history included: Doxycycline, reaction(s): "Known allergies: Doxycycline", notes: Known allergies: Doxycycline; Avelox, reaction(s): "Known allergies: Avelox", notes: Known allergies: Avelox. Vaccination history included: shingrix (Shingrix completed 23Oct2020), administration date: 23Oct2020, when the patient was 59-year-old, for Immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Oct2022, outcome "unknown" and all described as "Covid test date=Oct2022 / Covid test result=Positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Oct2022) Positive, notes: Nasal Swab.  Clinical course: Facility type vaccine was noted as pharmacy or drug store. The patient did not receive any other vaccine in four weeks. The patient did not receive any other medication in two weeks. The patient had covid prior to vaccination. Covid test post vaccination was noted as nasal swab on an unspecified date in Oct2022 and result noted as positive.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information provided in the narrative, a causal association between the events and the suspect drug cannot be completely excluded.,Linked Report(s) : US-PFIZER INC-202300078579 Same patient/vaccine, different dose and event;US-PFIZER INC-202300078592 Same patient/vaccine, different dose and event;
Pt recvd vax 13FEB92 9AM & @ 1145 pt had fever of 103 & started to scream w/o ceasing for 7 hrs; Tempra given temp never above 103; MD called p/5 hrs of screaming & took pt to see MD p/7 hrs of screaming;
One hour after shot, I had stabbing pains in my feet.  It lasted about 45 minutes.  An hour and a half after the shot I had extreme itching on my neck and scalp.  Then it spread to my palms and then feet.  As of 8:45pm, it is still extremely itchy on my feet and palms.
Pt stated was nauseated and had myalgias and headache, but no localized reaction. Symptoms resolved after 10 days duration.
Initial and follow-up information has been received from a registered nurse for the Pregnancy Registry for GARDASIL concerning a 16 year old female with asthma who on 24-SEP-2007 was vaccinated IM with a 0.5 ml first dose of GARDASIL (lot #654535/0960F).  On approximately 12-NOV-2007, the patient developed depression and was placed on tapering dose of PROZAC.  On 05-DEC-2007, the patient was vaccinated IM with a 0.5 ml second dose of GARDASIL (lot #654535/0960F).  Subsequently the patient became pregnant.  Unspecified medical attention was sought.  Last menstrual period was approximately 25-AUG-2007 and estimated date of delivery was 31-MAY-2007.  On approximately 10-DEC-2007, the patient developed nausea and was placed on therapy with PHENERGAN.  On 03-JAN-2008, the patient had vaginal spotting.  Abdominal ultrasound was within normal limits.  On 14-JAN-2008, the patient pelvic pain.  An gallbladder ultrasound on 14-JAN-2008 (also reported as 15-JAN-2008) was within normal limits.  On an unspecified date, the patient developed abdominal pain.  The patient had an ultrasound on 31-MAR-2008 (results not reported).  On 23-MAY-2008, the patient had a cesarean section due to cephalopelvic disproportion.  The patient gave birth to a normal male infant (weight 6 pounds, 11 ounces) that was given for adoption.  Upon internal review, cephalo-pelvic disproportion leading to a cesarean section was considered to be an other important medical event.  Additional information has been requested.
other zoster related injuries; shingles; Information has been received from a lawyer referring to a patient of unknown age and gender regarding a case in litigation. Information about concurrent condition, history condition and concomitant medication was not reported. In or about 2010, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) by a health care provider (HCP) at a clinic for the long-term prevention of shingles and zoster-related conditions. Subsequent to the inoculation, the patient was treated by a physician at the clinic for shingles and other zoster-related conditions(Ill-defined disorder). As a direct and proximate result of the use of the zoster vaccine live (ZOSTAVAX) vaccine, the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of shingles and other zoster-related conditions was considered to be not recovered and causal relationship was assessed as related.
suspected vaccination failure; I got it after my shot.; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The reporter stated that, got shingles after the shot. This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization for shingles, time to onset for event and laboratory confirmation for shingles were not provided.
Received information on a spontaneous report on 23JAN2018 and 25JAN2018 from personnel. The physician reported that on 23JAN2018, a patient received 5ml of BIOTHRAX vaccine rather than the prescribed 0.5ml amount. The subject experienced soreness at the site, and then developed mild headaches approximately 8 hours after the injection. No other complications were reported after 24 hours observation. The subject was restricted from caffeine and working out for the first 72 hours. It was also noted that he received a flu shot on 19DEC2017 and was on doxycycline for malaria prophylaxis. FOLLOW UP Information was received on 16FEB2018 from the physician. The physician reported that the patient was evaluated by medics and no evidence of lingering side effects was found. It was also noted that the patient felt excellent, had no signs of complications at the site, and no signs or symptoms that would lead one to believe he is not in perfect/usual health. No additional information is expected.
After Dose 1 no outside treatment and after Dose 2 basically told it would go away those are normal reactions from the vaccine. Then after 30 days of Dose 2 on January 1, 2021 I started to hemorrhaging after 3 years of no menstrual. I was having vagina bleeding that was continuously that didn't stop. I went to my PCP and OB couldn't tell me what was happening had EKG. I started experiencing high blood pressure followed up with Cardiologist found my right side is enlarged. I was placed on Cholesterol and High blood pressure medication. In November 2021 was hospitalized at a HCF for 7 days had tissue removed from my thigh my A1C levels was high and blood pressure. I continued wood care treatment. I was released from the surgeon on January 6, 2022 and on January 7, 2022 developed kidney stones and left side pain. I had a ultrasound on January 17, 2022. On January 18, 2022 was transported to another HCF at  hospital had heart attack. Then on January 19, 2022 admitted had heart catherization placed 2 stents in one artery the was blocked discharged on January 21, 2022. The worse part is nobody can tell me what's going on had no problems before vaccine.
A report was received from a health care professional on 27 October 2003 concerning a 3 year old male vaccinee who inadvertently received Fluvirin vaccine on 21 October 2003. On 21 October 2003, the vaccinee was inadvertently administered Fluvirin. No adverse event was reported. There was insufficient information to determine the reporter's causality assessment. Follow up pending.
This spontaneous report was received from a a registered nurse refers to a 13 year old female patient with penicillin allergy and amoxicillin allergy and no pertinent medical history. On 30-NOV-2009, the patient was vaccinated with the first dose of GARDASIL (Lot # 0672Y, Exp date: 19-SEP-2011). On 29-NOV-2010, the patient was vaccinated with the second dose of GARDASIL (Lot # 0992Z, Exp date: 14-OCT-2012). The patient had no concomitant medications. The nurse reported that the patient developed numbness in the arm (injection site arm) immediately following the first and second dose of GARDASIL. No treatment was given. No laboratories were performed. The numbness resolved after an unspecified time period after each dose of GARDASIL. The patient sought medical attention, contacted office. The nurse had no other information about the numbness at the time of the call. Additional information has been requested.
Headache, Fever, Angioedema, facial pain, stiff neck Received vaccine 1/5/21. On 1/6/21 noted pounding headache and stiff neck. Later that day right eye became swollen, and developed neuropathic-type pain on left side of face and left ear. Unable to chew or use electric toothbrush on the left side. Temperature up to 100.6F. Symptoms peaked 48 hours after vaccine administration. No loss of facial muscle tone, and no loss of smile. Saw primary care provider for evaluation on 1/12/21. Treated with ibuprofen, diphenhydramine and cetirizine. No prior positive COVID test (hx of 2 negative tests).
This spontaneous report was received from the patient's wife via a specialty pharmacy regarding to a 77 years old male patient. The patient's medical history included allergy to morphine, related nonsteroidal anti-inflammatory drugs (NSAIDS) and opium (hypersensitivity). His concomitant medications included lisinopril, amlodipine besylate, finasteride, folic acid, acyclovir, bimatoprost (LUMIGAN), doxazosin and ibuprofen. On 22-FEB-2013 (reported as five years ago), the patient started therapy with ruxolitinib phosphate(JAKAFI) tablets, 20 mg, bid, taken orally, lot # 6026224 with expiration date 30-JUN-2020 and lot # 5996751 with expiration date 31-JUL-2020 for iron deficiency.  On 20-MAR-2018, the patient had outpatient surgery of his back to repair the bones around the top of the spine (spinal disorder). Furthermore, it was reported that more surgery was planned to repair bones around the same area on an unspecified date in June 2018. On 18-OCT-2018 at 3:00pm (also reported as yesterday), the patient was vaccinated with PNEUMOVAX 23 (dose, strength, route of administration, anatomical location, lot # and expiration date were not provided) for pneumonia prophylaxis. Furthermore, the patient developed pneumonia. On the same date at 9:30 pm, the patient woke up with a fever and started to shake violently (tremor). He felt strange (abnormal feeling) and could not sleep during the night, but when the morning came he felt asleep and had hard time waking up (sleep disorder). At the reporting time, the patient was recovering from the spinal disorder, and was not recovered from the following events: pneumonia, tremor, abnormal feeling and sleep disorder.  The causal assessment of spinal disorder, anemia, pneumonia, pyrexia, tremor, abnormal feeling and sleep disorder with PNEUMOVAX 23 was not provided. Upon internal review, pneumonia event was determined to be medically significant.
I took the Pfizer vaccine on the morning of  April 3, 2021. Four days later, I woke up and the left side of my face was numb. I contacted my primary care doctor and was directed to go to the ER due to medical concerns. After the doctor examined me, I was diagnosed with Bell's Palsy. I was prescribed prednisone 20 MG Tablets that I took 3 tabs daily for 7 days, then 2 tabs for 4 days, then 1 tab for 4 days then 1/2 tab for 4 days then stop. I also took 1 valacyclovir 1000MG tablet by mouth 3 times daily for 7 days. After completing the medication, I recovered 100%.
Fever up to 102 starting at 6p, fatigue bodyaches and vomiting started at 1am.
Hospitalization for 5 days, needed max of 5 L NC Covid 19 PNA
arm soreness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm soreness) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (arm soreness). At the time of the report, PAIN IN EXTREMITY (arm soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications was reported.  No treatment medications was provided For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-041797 (E2B Linked Report).; Sender's Comments:  MOD-2021-041797:
Extreme ulcerative colitis flare: diarrhea, abdominal pain, multiple bowel movements. Colonoscopy one week earlier showed no signs of flare, all was well, then 2 days after shot, it flared. This also occurred with shots 1-3, but I thought those were just "normal" flares. My medical team now believes these were reactions to the vaccination.
30 patients received Monovalent Moderna Vaccine past the manufacturers expiration date; No adverse event; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (30 patients received Monovalent Moderna Vaccine past the manufacturers expiration date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (30 patients received Monovalent Moderna Vaccine past the manufacturers expiration date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (30 patients received Monovalent Moderna Vaccine past the manufacturers expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (30 patients received Monovalent Moderna Vaccine past the manufacturers expiration date).    This case contains information for the 23rd of 30 adult patients described by the reporter.  Concomitant Medication use information was not provided by reporter.  There was 13, 11, and 6 different doses given. The 30 patients received Monovalent Moderna Vaccine past the manufacturer's expiration date.   The batch lot number was reported as 022D21A which was expired on 20 April 2022. The Lot number 033F21A which was expired on 08 April 2022. The Lot number 037C21A expired on 02 January 2022.  Treatment Medication use information was not provided by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-703461 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-703461:Master case
I experienced numbness in my left hand shortly after my vaccine, which lasted about a day and on day 8 on 2/23/2021, I had a large reddish-pink raised oval mark on my arm around the injection site and a series of reddish -pink  horizontal itchy hives   a few inches  below the  injection site mark. The itchiness subsided on day 9 and by day 11, the entire reaction on my arm disappeared .
ACUTE ST ELEVATION MI, INFERIOR WALL REVERSIBLE ISCHEMIC NEUROLOGIC DEFICIT SYNDROME CARDIOGENIC SHOCK CRITICAL ILLNESS POLYNEUROPATHY 9/25/2022,  9/27/2022,  10/7/2022 -- RECURRENCE OF SAME SYMPTOMS
itching; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itching) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRURITUS (itching). At the time of the report, PRURITUS (itching) outcome was unknown.            Concomitant and Treatment medications were not provided by reporter.
Narrative:  COVID infection following COVID vaccine series 05/12, Pfizer, dose #1 06/02, Pfizer, dose #2 12/24 COVID swab, result: detected 12/20 pt cc: cough, loss of taste or smell, rhinorrhea, diarrhea, nausea exposure: family 12/29 clinically resolved
This is a prospective pregnancy case. This 38-year-old female subject was enrolled in a study. The subject received BOOSTRIX (intramuscular) .5 ml on 12th December 2014. The subject's last menstrual period was on 18th April 2014 and estimated date of delivery was 23rd January 2015. The subject received BOOSTRIX at week 34 of the pregnancy and during the third trimester of pregnancy. On an unknown date, an unknown time after receiving BOOSTRIX the subject developed vaccine exposure during pregnancy (Non-serious). The outcome of vaccine exposure during pregnancy was unknown. The pregnancy was ongoing. Additional information received on 12 December 2014: The last menstrual period was not reported but was calculated with the due date. The type of conception was not reported.
Information has been received from a physician concerning an 11 year old female who on 05-Sep-2006 was vaccinated intramuscularly with the first dose of HPV rL1 6 11 16 18 VLP vaccine (yeast). On approximately 05-Sep-2006, the patient noted her menstrual cycle increased from every month to every two weeks. The patient sought unspecified medical attention. At the time of this report, the outcome of the event was unknown. Additional information has been requested.